BRPI0809995A2 - Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv - Google Patents

Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv

Info

Publication number
BRPI0809995A2
BRPI0809995A2 BRPI0809995-2A BRPI0809995A BRPI0809995A2 BR PI0809995 A2 BRPI0809995 A2 BR PI0809995A2 BR PI0809995 A BRPI0809995 A BR PI0809995A BR PI0809995 A2 BRPI0809995 A2 BR PI0809995A2
Authority
BR
Brazil
Prior art keywords
ameliorating
peptide
patient
composition
methods
Prior art date
Application number
BRPI0809995-2A
Other languages
English (en)
Inventor
Brian L Bray
Jie Di
David Heilman
Peter Silinski
Scott Webb
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of BRPI0809995A2 publication Critical patent/BRPI0809995A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0809995-2A 2007-04-03 2008-04-02 Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv BRPI0809995A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92170407P 2007-04-03 2007-04-03
PCT/US2008/004307 WO2008124013A1 (en) 2007-04-03 2008-04-02 Novel formulations for delivery of antiviral peptide therapeutics

Publications (1)

Publication Number Publication Date
BRPI0809995A2 true BRPI0809995A2 (pt) 2015-07-21

Family

ID=39831248

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809995-2A BRPI0809995A2 (pt) 2007-04-03 2008-04-02 Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv

Country Status (11)

Country Link
US (1) US20090068243A1 (pt)
EP (1) EP2139526A4 (pt)
JP (1) JP2010523564A (pt)
KR (1) KR20100016142A (pt)
CN (1) CN101678125A (pt)
AR (1) AR065941A1 (pt)
BR (1) BRPI0809995A2 (pt)
CA (1) CA2682848A1 (pt)
MX (1) MX2009010689A (pt)
TW (1) TW200902043A (pt)
WO (1) WO2008124013A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
KR20100080812A (ko) * 2007-09-25 2010-07-12 트라이머리스, 인코퍼레이티드 치료용 항-ｈｉｖ 펩티드의 합성 방법
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
JP2013543898A (ja) * 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物
US20140294977A1 (en) 2011-11-23 2014-10-02 Durect Corporation Radiation-Sterilized Biodegradable Drug Delivery Composition
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途
CN112851789B (zh) * 2021-02-04 2022-10-18 大理大学 一种脑靶向hiv进入抑制剂多肽及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) * 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) * 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) * 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) * 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1993007603A1 (en) * 1991-10-04 1993-04-15 Cornett Robert H Approaching emergency vehicle warning system
JP4010560B2 (ja) * 1992-07-20 2007-11-21 ドューク ユニバーシティー Ｈｉｖ複製を阻害する化合物
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US5474058A (en) * 1994-11-30 1995-12-12 Thayer Medical Corporation MDI ventilator dispenser with bi-directional nozzle
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
AU723537B2 (en) * 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) * 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP1043031A4 (en) * 1997-12-26 2007-05-02 Astellas Pharma Inc MEDICINAL COMPOSITIONS WITH PROLONGED RELEASE
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6541020B1 (en) * 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
JP4361710B2 (ja) * 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
US6733714B2 (en) * 2001-08-13 2004-05-11 Edwin J. Oakey Method for forming high-impact, transparent, distortion-free polymeric material
CN1100564C (zh) * 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
CN1929860A (zh) * 2004-03-15 2007-03-14 特里梅里斯公司 HIV gp41衍生肽的位点特异性化学修饰
JP4805911B2 (ja) * 2004-03-15 2011-11-02 ネクター セラピューティクス Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
DK2167039T3 (en) * 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
KR20100080812A (ko) * 2007-09-25 2010-07-12 트라이머리스, 인코퍼레이티드 치료용 항-ｈｉｖ 펩티드의 합성 방법

Also Published As

Publication number Publication date
JP2010523564A (ja) 2010-07-15
CN101678125A (zh) 2010-03-24
TW200902043A (en) 2009-01-16
MX2009010689A (es) 2009-12-14
US20090068243A1 (en) 2009-03-12
EP2139526A4 (en) 2010-07-14
KR20100016142A (ko) 2010-02-12
CA2682848A1 (en) 2008-10-16
AR065941A1 (es) 2009-07-15
WO2008124013A1 (en) 2008-10-16
EP2139526A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
BRPI0809995A2 (pt) Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv
BRPI0907036A2 (pt) Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
BRPI0917119A2 (pt) composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação.
BRPI0816130A2 (pt) Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo.
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0911427A2 (pt) complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI0814939A2 (pt) Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
CO6280466A2 (es) Forma de dosificacion farmaceutica de liberacion controlada
BRPI1008971A2 (pt) métodos para preparar uma proteína biológica condicionalmente ativa, e um modificador de resposta biológica condicionalmente ativo, proteína biológica condicionalmente ativa, e, composição farmacêutica
BRPI0807908A2 (pt) Melhoramentos em composições medicinais.
BRPI0812384A2 (pt) Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
BRPI0816814A2 (pt) composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
BRPI0924140A2 (pt) pinça de microcirurgia, em particular pinça de capsulorrexe por microincisão
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
WO2009068708A3 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
BRPI0717507A2 (pt) métodos para tratar, prevenir e diagnosticar infecção ttv de porcine

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/16 (2006.01), A61K 9/00 (2006.01), A61K 38